Oxcarbazepine for refractory epilepsy
systematic review of the literature
Keywords:
Anticonvulsants, Epilepsy, Review [Publication Type], Seizures, Oxcarbazepine [Substance name]Abstract
CONTEXT AND OBJECTIVE: It has been estimated that 50 million people worldwide suffer from epilepsy and around 30% will not achieve adequate control over the disease. The aim was to evaluate the effectiveness of oxcarbazepine for refractory partial or generalized epilepsy. METHODS: Systematic review. A search was conducted in the PubMed, Lilacs, EMBASE and CENTRAL databases. Studies were analyzed using the Cochrane Collaboration methodology. RESULTS: Four randomized clinical trials of medium to poor methodological quality were included. Among the adult patients, the chances that they would obtain a 50% reduction in seizure frequency were greater after using oxcarbazepine at doses of 600 mg (relative risk, RR 2.11; 95% confidence interval, CI 1.32 to 3.35), 1,200 mg (RR 3.24; 95% CI 2.11 to 4.98) and 2,400 mg (RR 3.83; 95% CI 2.59 to 5.97). Among the children, the response in the group using oxcarbazepine was also greater (RR 2.11; 95% CI 1.32 to 3.35). The oxcarbazepine doses of 1,200 mg (RR 17.59; 95% CI 2.37 to 130.35) and 2,400 mg (RR 25.41; 95% CI 6.26 to 103.10) were effective for keeping patients probably free from seizures, but the dose of 600 mg was not. There was no significant difference between oxcarbazepine and carbamazepine for controlling the crises. CONCLUSIONS: There is moderate evidence indicating that oxcarbazepine is effective as an alternative treatment for partial or generalized epilepsy in children and adults who were refractory to previous treatment.
Downloads
References
Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-2.
Smith PE; UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure. 2001;10(2):87-91.
Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-120.
Schmidt D, Sachdeo R. Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use. Epilepsy Behav. 2000;1(6): 396-405.
Schmidt D. How reliable is early treatment response in predicting long-term seizure outcome? Epilepsy Behav. 2007;10(4):588-94.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Di- mensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408-12.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from: http://www.cochrane.org/resources/ handbook/. Accessed in 2009 (Jun 24).
Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26(3):451-60.
Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clini- cal trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27(3):205-13.
Kutluay E, McCaque K, D’Souza J, Beydoun A. Safety and tolerability of ox- carbazepine in elderly patients with epilepsy. Epilepsy Behav. 2003;4(2): 175-80.
Passarella B, Nozzoli C. Long-term treatment with oxcarbazepine in clinical practice. Funct Neurol. 2005;20(3):131-3.
Albani F, Grassi B, Ferrara R, et al. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure. 2004;13(4):254-63.
Albani F, Bisulli F, Bartezaghi M, et al. Multicentre observational study evalu- ating immediate and progressive switching from carbamazepine to oxcarba- zepine in patients with epilepsy. Funct Neurol. 2007;22(2):111-5.
Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 2000;54(12):2245-51.
Beydoun A, Sachdeo RC, Kutluay E, McCague K, D’Souza J. Sustained efficacy and long- term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia. 2003;44(9):1160-5.
Bill PA, Vigonius U, Pohlmann H. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27(3): 195-204.
Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65(9):1370-5.
Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57(5):864-71.
Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine in a monotherapy trial for par- tial seizures--placebo-controlled studies in neurology: where do they stop? Neurology. 1999;53(9):2211-2.
Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41(12):1597-607.
Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 2000;54(12): 2237-44.
Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarba- zepine and carbamazepine: a double-blind study. Epilepsy Res. 1987;1(5):284-9.
Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia. 2002;43(5):535-8.
Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand. 2006;114(3):157-68.
Schmidt B. Clinical development of antiepileptic drugs in adults. Neurotherapeutics. 2007;4(1):62-9.
Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are dis- tinctly different antiepileptic drugs? Epilepsy Behav. 2004;5(5):627-35.
Vianna JBM. O teste oral de tolerância a glicose é freqüentemente alterado em pacientes com epilepsia de difícil controle. [Thesis] São Paulo: Universidade Federal de São Paulo — Escola Paulista de Medicina; 2006.
